Wu X, Blanck A, Olovsson M, Möller B, Lindblom B
Section for Obstetrics and Gynecology, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Acta Obstet Gynecol Scand. 2001 Jun;80(6):497-504.
To investigate whether basic fibroblast growth factor (bFGF) is involved in the growth regulation of human uterine leiomyomas the expression of bFGF and its receptors was measured in leiomyomas and myometrium obtained under different endocrine conditions.
The expression of bFGF, fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor receptor 2 (FGFR2) was analyzed by immunohistochemistry and Western blot.
Twenty-seven women with leiomyomas included eight in the proliferative phase, seven in the secretory phase, six after menopause and six after GnRHa treatment. In the proliferative phase, bFGF staining in leiomyomas was significantly stronger than in any other leiomyoma group. After GnRHa treatment, the expression of bFGF in both leiomyomas and myometrium was weaker than in the proliferative phase. The staining of FGFR1 was less intense in proliferative phase myometrium than in myometrium from any other group, significantly weaker than in the secretory phase. The leiomyomas demonstrated homogeneous cytoplasmic FGFR1 staining that was similar in all groups, except in the GnRHa treated patients where a more intense staining was observed, significantly stronger than in proliferative phase leiomyomas. No tissue differences were observed for staining of FGFR2 and no significant differences were observed between the different groups. Slightly less staining of FGFR2 was found in leiomyomas in the secretory phase but it did not reach statistical significance. The specificity of immunostaining was confirmed by Western blot.
We suggest that the regulation of bFGF, and to some extent also its receptors in leiomyomas and in myometrium, is influenced by sex steroid hormones. However, the lack of differences in expression between leiomyomas and myometrium favors the view that bFGF does not necessarily contribute to the differences in growth regulation in these tissues.
为研究碱性成纤维细胞生长因子（bFGF）是否参与人类子宫平滑肌瘤的生长调节，我们检测了在不同内分泌条件下获取的平滑肌瘤和子宫肌层中bFGF及其受体的表达。
采用免疫组织化学和蛋白质印迹法分析bFGF、成纤维细胞生长因子受体1（FGFR1）和成纤维细胞生长因子受体2（FGFR2）的表达。
27例平滑肌瘤患者中，8例处于增殖期，7例处于分泌期，6例绝经后，6例接受促性腺激素释放激素类似物（GnRHa）治疗后。在增殖期，平滑肌瘤中bFGF染色明显强于其他任何平滑肌瘤组。GnRHa治疗后，平滑肌瘤和子宫肌层中bFGF的表达均弱于增殖期。增殖期子宫肌层中FGFR1的染色强度低于其他任何组的子宫肌层，明显弱于分泌期。平滑肌瘤显示均匀的细胞质FGFR1染色，所有组相似，但GnRHa治疗的患者染色更强，明显强于增殖期平滑肌瘤。FGFR2染色未观察到组织差异，不同组之间也未观察到显著差异。分泌期平滑肌瘤中FGFR2染色略少，但未达到统计学意义。蛋白质印迹法证实了免疫染色的特异性。
我们认为，bFGF及其在平滑肌瘤和子宫肌层中的受体调节在一定程度上受性类固醇激素影响。然而，平滑肌瘤和子宫肌层之间表达缺乏差异支持了bFGF不一定导致这些组织生长调节差异的观点。
